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Dermatopontin is a recently discovered extracellular
matrix protein with proteoglycan and cell-binding
properties and is assumed to play important roles in
cell–matrix interactions and matrix assembly. In this
study we examined the expression of dermatopontin
mRNA and protein in skin fibroblast cultures from
patients with hypertrophic scar and patients with sys-
temic sclerosis. Dermatopontin mRNA and protein
levels were reduced in fibroblast cultures from hyper-
trophic scar lesional skin compared with fibroblasts
from normal skin of the same hypertrophic scar
patient. Fibroblast cultures from systemic sclerosis
patient involved skin also showed significantly reduced
expression of dermatopontin compared with normal
skin fibroblasts from healthy individuals. We also
Hypertrophic scar (HS) and systemic sclerosis (SSc)are fibrotic disorders characterized by excessiveaccumulation of collagen (Fleischmajer, 1993;Lapie`re, 1993). Although unregulated productionof collagen is considered to be a crucial process in
the development of fibrosis in HS and SSc, other extracellular
matrix molecules also play an important part in the pathogenesis
of fibrosis (Vuorio et al, 1991; Xu et al, 1991; Lacour et al, 1992;
Tan et al, 1993).
Dermatopontin (tyrosine-rich acidic matrix protein) is a recently
discovered, 22 kDa extracellular matrix protein (Neame et al, 1989;
Cronshaw et al, 1993; Superti-Furga et al, 1993; Okamoto et al,
1996). The protein displays a striking tendency to bind to the small
dermatan sulfate proteoglycans (Neame et al, 1989; Okamoto et al,
1996). Furthermore, dermatopontin promotes cell attachment and
cytoplasmic spreading of dermal fibroblasts, where it is assumed
the adhesion activity is mediated by cell surface integrin binding
(Lewandowska et al, 1991). Recently, dermatopontin has been
shown to bind type I collagen and accelerate the assembly of
collagen into fibrils (MacBeath et al, 1993). Thus, dermatopontin
is thought to be a multifunctional protein of the extracellular matrix.
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investigated the effects of cytokines and matrix colla-
gen on dermatopontin expression in normal cultured
fibroblasts. Transforming growth factor-b1 increased
dermatopontin mRNA and protein levels, while
interleukin-4 reduced dermatopontin expression. Sub-
strate coated with type I collagen reduced dermato-
pontin mRNA levels, the reduction being more
prominent in three-dimensional collagen matrices.
Our results suggest that the decreased expression of
dermatopontin is associated with the pathogenesis of
fibrosis in hypertrophic scar and systemic sclerosis,
and that the effect of the cytokines and matrix collagen
on dermatopontin may have important implications
for skin fibrosis. Key words: skin fibrosis. J Invest Dermatol
112:706–710, 1999
Although dermatopontin appears to be involved in the formation
of some pathologic conditions of connective tissue, such as wound
healing, fibrosis, and tumor invasion, the regulation of dermato-
pontin gene expression in these situations is poorly understood. In
this study we investigated the expression of dermatopontin in skin
fibroblast cultures from patients with HS and SSc, and assessed the
effects of transforming growth factor-β (TGF-β), interleukin-4
(IL-4), and collagen matrices on gene expression.
MATERIALS AND METHODS
Patients HS samples were obtained from scar lesions from five patients
undergoing reconstructive surgery, and from normal tissues adjacent to scar
lesions for use as control specimens. The age of HS patients was 18–42 y.
The disease duration after injury was from 4 mo to 3 y. Nine patients
with SSc, who fulfilled the criteria for diagnosis (American Rheumatism
Association, 1980), and nine sex-matched and age-matched normal indi-
viduals as controls were also studied. The age of normal skin donors ranged
from 37 to 52 y (average 42 y), and the age of SSc patients was 35–54 y
(average 44 y). SSc patients had disease durations of 6 mo to 12 y; seven
of nine patients had the disease for less than 4 y. All SSc skin specimens
were obtained from the dorsal forearm. The fibrotic changes of HS and
SSc skin were confirmed histopathologically.
Cell cultures Establishment of human fibroblasts from skin samples was
performed as described by Hayflick and Moorhead (1961) with some
modifications. Full-thickness skin specimen from SSc and HS patients and
normal individuals were cut into small pieces, placed on the culture
flask, and cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine,
100 units per ml penicillin, and 50 units per ml streptomycin in a humid
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atmosphere containing 5% CO2 at 37°C. When outgrowth of fibroblasts
from the pieces of skin samples reached some 75% of the culture surface,
subculture was performed by 0.25% trypsin treatment. Fibroblasts at four
to seven passages were used for experiments. Human recombinant TGF-
β1 (R&D Systems, Minneapolis, MN) and human recombinant IL-4
(provided by Ono Pharmaceutical, Osaka, Japan) were used for cytokine
studies. Viable cell number was determined by using a hemocytometer in
a Trypan Blue stain.
For three-dimensional collagen gels, collagen (bovine dermal type I
collagen dissolved at 3 mg per ml in 50 mM acetic acid) was prepared by
mixing type I collagen and 10% FBS in DMEM at pH 7.4. Skin fibroblasts
from subconfluent cultures were mixed with the collagen solution to a
final concentration of 5 3 105 cells per ml, 1 mg collagen per ml, and 1%
FBS. The collagen cell suspensions (15 ml) were immediately placed on
to 100 mm tissue culture dishes and incubated for 2 h at 37°C. After
polymerization, 15 ml of 1% FBS/DMEM was added to each dish and
floating collagen gels were obtained by detaching the gel from the plate.
For control monolayer cultures trypsinized fibroblasts from subconfluent
cultures were seeded on plastic culture dishes and cultured in 1% FBS/
DMEM.
For planar type I collagen coating, the bovine collagen preparation was
diluted and added to plastic dishes at a final concentration of up to 125 µg
per ml. Coated dishes were allowed to dry and rinsed with PBS before use.
Northern blot analysis Total cellular RNA was extracted using the
guanidinium isothiocyanate method (Chomczynski and Sacchi, 1987). An
aliquot of total RNA (5 µg per lane) was size fractionated by 1% agarose
gel electrophoresis and transferred to a nylon filter. Equal loading was
confirmed by ethidium bromide staining. Blots were prehybridized, hybrid-
ized, autoradiographed, and stripped for rehybridization as previously
described (Kuroda and Shinkai, 1997). Probes used for hybridization were
a 0.7 kb dermatopontin human cDNA (Superti-Furga et al, 1993) (a
generous gift from Dr. A. Superti-Furga, University Children’s Hospital,
Switzerland) and, as a control of constitutive expression, a 0.8 kb human
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA (Arcrari et al,
1984). The intensities of specific mRNA were quantitated with a Fuji
Bio-Image analyzer BAS2000 (Fuji Photo Film, Kawasaki, Japan).
Measurement of dermatopontin production Confluent fibroblasts
were incubated in serum-free DMEM for 24 h, cell culture media collected
and protein precipitated by the addition of trichloroacetic acid. Samples
corresponding to the original volume of medium were electrophoresed
on 15% sodium dodecyl sulfate–polyacrylamide gel electrophoresis. For
immunoblotting, proteins were electrophoretically transferred to poly-
vinylidene fluoride membranes (Millipore, Bedford, MA) in transfer buffer
(25 mM Tris, 200 mM glycin, 20% methanol) for 4 h at 60 V. Efficient
transfer was ensured by amid black staining for the lanes of molecular
weight markers. Dermatopontin was detected by incubation with anti-
dermatopontin rabbit serum (Okamoto et al, 1996) and visualized by the
biotin–avidin–peroxidase complex system (Zymed Laboratories, South San
Francisco, CA) using diaminobenzidine as the chromogenic substrate.
Dermatopontin band intensities were quantitated by densitometry. In a
preliminary study serial dilutions of each sample were used to prepare
immunoblotting analyses and amounts of samples within the linear range
for this assay were determined. Total protein synthesis was measured by
incubating cells in serum-free DMEM containing 5 µCi [3H]leucine per
ml for 24 h. Total [3H]leucine incorporation into proteins was measured
by trichloroacetic acid precipitation.
RESULTS
Reduced expression of dermatopontin mRNA and protein
in HS fibroblasts Northern blot analysis was performed on five
pairs of fibroblast cultures established from lesional skin and normal
skin adjacent to scar lesions from the same patients (Fig 1a).
Dermatopontin mRNA levels, after correction with respect to
GAPDH, were clearly reduced in fibroblast cultures from lesional
skin compared with normal fibroblasts (Fig 1b). Immunoblotting
analysis also revealed that the ratio of 22 kDa dermatopontin band
intensity to total protein synthesis was lower in fibroblast cultures
from lesional skins compared with fibroblasts from normal skins
(Fig 2). The relative decrease in dermatopontin synthesis was
approximately coincident with reduction in dermatopontin mRNA
levels. The measurement of cell numbers at the end of the culture
period revealed no significant differences between scar and normal
fibroblasts. Thus, the reduction of dermatopontin synthesis in scar
Figure 1. Reduced expression of dermatopontin mRNA in HS
fibroblast cultures. (a) Confluent fibroblasts from scar lesions (S) and
normal skin (N) of five patients (HS1–HS5) were incubated with serum-
free DMEM for 24 h. After extraction of total RNA, northern blot analysis
were performed. (b) Levels of dermatopontin mRNA were quantitated by
densitometric scanning and corrected for GAPDH mRNA.
Figure 2. Reduced dermatopontin protein levels in HS fibroblast
cultures. (a) Confluent fibroblasts from scar lesions (S) and normal skin
(N) of five patients (HS1–HS5) were incubated with serum-free DMEM
for 24 h. After the precipitation of cell culture media, the expression of
dermatopontin was studied by immunoblotting analysis. (b) Dermatopontin
protein levels were quantitated by densitometric scanning and corrected
for total radiolabeled protein.
fibroblasts was due to the specific reduction of dermatopontin
biosynthesis.
Significant reduction of dermatopontin mRNA and protein
levels in SSc fibroblasts Dermatopontin mRNA and protein
levels were examined in cultured fibroblasts established from nine
SSc patient involved skin samples and nine normal skin samples
from healthy individuals. Northern blot analysis demonstrated a
significantly lower level of dermatopontin mRNA in SSc fibroblasts
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Figure 3. Significant reduction of dermatopontin mRNA levels in
SSc fibroblasts. (a) Confluent fibroblasts from normal healthy controls
and SSc patients were incubated with serum-free DMEM for 24 h. After
extraction of total RNA, northern blot analysis was performed. (b) Levels
of dermatopontin mRNA were quantitated by densitometric scanning and
corrected for GAPDH mRNA. The results from control and SSc fibroblast
groups were compared using the Mann–Whitney U test.
Figure 4. Reduction of dermatopontin protein levels in SSc
fibroblasts. (a) Confluent fibroblasts of normal healthy controls and SSc
patients were incubated with serum-free DMEM for 24 h. After
precipitation of cell culture media, the expression of dermatopontin were
studied by immunoblotting analysis. (b) Dermatopontin protein levels were
quantitated by densitometric scanning and corrected for total radiolabeled
protein. The results from control and SSc fibroblast groups were compared
using the Mann–Whitney U test.
compared to control fibroblasts (p , 0.01) (Fig 3), with dermato-
pontin mRNA only faintly detectable in fibroblasts from two
SSc patients (patients 1 and 4). This was in agreement with
immunoblotting analysis, which revealed that the ratio of dermato-
pontin band intensity to total protein synthesis was significantly
lower in SSc fibroblasts compared with control fibroblasts (p , 0.05)
(Fig 4). Measurement of cell numbers at the end of the culture
period revealed no significant differences between SSc and normal
fibroblasts. Thus, the reduction of dermatopontin synthesis in SSc
fibroblasts was due to the specific reduction of dermatopontin
biosynthesis.
Dermatopontin expression is differentially regulated by
TGF-b1 and IL-4 The effects of TGF-β1 and IL-4 on dermato-
pontin expression were examined on normal skin cultured
fibroblasts. TGF-β1 enhanced dermatopontin mRNA levels in a
Figure 5. Concentration-dependent and time-dependent regulation
of dermatopontin mRNA levels by TGF-b1 and IL-4 in normal
fibroblasts. Confluent normal fibroblasts were rinsed with PBS followed
by synchronization with serum-free DMEM for 6 h, then incubated in
serum-free DMEM for 24 h with various cytokine concentrations or for
various intervals with 2.5 ng per ml TGF-β1 or 5 units per ml IL-4. After
extraction of total RNA, the expression of dermatopontin mRNAs was
studied by northern blot analysis. (a) TGF-β1; (b) IL-4.
Figure 6. Effect of TGF-b1 and IL-4 on dermatopontin protein
expression in normal fibroblasts. (a) Confluent normal fibroblasts were
rinsed with PBS followed by synchronization with serum-free DMEM for
6 h, then incubated in serum-free DMEM for 24 h with or without 5 ng
per ml TGF-β1 or 5 units per ml IL-4. After precipitation of cell culture
media, the expression of dermatopontin were studied by immunoblotting
analysis. (b) Dermatopontin protein levels were quantitated by densitometric
scanning and corrected for total radiolabeled protein. Data are mean 6 SD
of triplicate cultures. TGF-β1; p , 0.001; IL-4, p , 0.001.
concentration-dependent manner up to 10 ng per ml (Fig 5a).
TGF-β1 response time-course experiments showed a steady increase
in dermatopontin mRNA levels during the 48 h of the experiment.
After 48 h incubation, 2.5 ng TGF-β1 per ml showed a 3.4-
fold increase in dermatopontin mRNA compared with untreated
samples. In contrast, incubation of cultured cells with IL-4 resulted
in a significant decrease in dermatopontin mRNA levels in a
concentration-dependent (up to 10 ng per ml) and time-dependent
manner (Fig 5b). After 48 h incubation, 5 units per ml IL-4
resulted in a 77% decrease in dermatopontin mRNA levels.
Immunoblotting analysis revealed that the ratio of dermatopontin
production to total protein synthesis was increased by TGF-β1 and
decreased by IL-4 in normal skin cultured fibroblasts (Fig 6).
Twenty-four hour incubation with TGF-β1 (5 ng per ml) or IL-4
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Figure 7. Matrix collagen downregulates dermatopontin gene
expression. (a) Normal fibroblasts from subconfluent cultures were seeded
on to plastic culture dishes coated with various concentrations of type I
collagen, and incubated in serum-free DMEM for 24 h. After extraction
of total RNA, northern blot analysis were performed. (b) Normal fibroblasts
from subconfluent cultures were grown on untreated plastic culture dishes
as monolayer cultures (ML) or in three-dimensional collagen gel (CG) for
24 h with 1% FBS/DMEM. Northern blot analysis were performed and
levels of dermatopontin mRNA were quantitated by densitometric scanning
and corrected for respective 28S rRNA levels.
(5 units per ml) resulted in a 2.5-fold increase and an 82% decrease,
respectively, as compared with untreated samples. Incubation with
TGF-β1 and IL-4 slightly increased cell numbers to 1.2-fold each.
Thus, TGF-β1 and IL-4 both modulate the specific biosynthesis
of dermatopontin.
Downregulation of dermatopontin expression by matrix
collagen To evaluate the effects of matrix collagen on dermato-
pontin expression, we cultured normal skin fibroblasts on type I
collagen-coated dishes and in three-dimensional collagen gels.
Substrata coated with type I collagen reduced dermatopontin
mRNA levels in proportion to the concentration of coated collagen
(Fig 7a). A collagen concentration of 125 µg per ml reduced
dermatopontin mRNA levels by 40% compared with uncoated
dishes. When fibroblasts were cultured in three-dimensional colla-
gen gels, the reduction in dermatopontin mRNA levels was more
prominent: µ80% reduction from levels observed in monolayer
cultures on uncoated dished (Fig 7b).
DISCUSSION
In the current study we have shown that dermatopontin mRNA
and protein levels were significantly reduced in cultured fibroblasts
established from fibrotic tissues of HS and SSc patients. Thus, the
impaired expression of dermatopontin may be associated with the
pathogenesis of fibrosis in HS and SSc.
Dermatopontin plays an important part in cell–matrix interactions
and matrix assembly. These functions are thought to be greatly
affected by small dermatan sulfate proteoglycans. As originally
shown by Neame et al (1989), dermatopontin displays a striking
tendency to copurify with the small dermatan sulfate proteoglycans.
We have recently reported that dermatopontin binds to decorin, a
major component of the small dermatan sulfate proteoglycans in
the dermis (Okamoto et al, 1996). The cell adhesion activity of
dermatopontin is completely inhibited by intact small dermatan
sulfate proteoglycans (decorin and biglycan), but not by chondroitin
sulfate/keratan sulfate proteoglycans (Lewandowska et al, 1991).
Furthermore, dermatopontin accelerates small diameter collagen
assembly (MacBeath et al, 1993), while decorin markedly delays
fibril formation (Vogel et al, 1984). These findings suggest that the
two molecules may help regulate the assembly and turnover of
collagen in the extracellular matrix through their diverse effect. In
fibrosing skin diseases, the expression of decorin is also altered.
Decorin mRNA levels vary in SSc cultured fibroblasts (Vuorio
et al, 1991) and expression is decreased in keloid fibroblasts (Tan
et al, 1993). Therefore, the altered expression of dermatopontin
and decorin may greatly influence cell behavior and fibril formation
in HS and SSc.
In our study, not every SSc fibroblast expressed low levels of
dermatopontin. Although we were unable to demonstrate a positive
association between dermatopontin expression and clinical or
histologic findings, there still remains a possibility that patient age
or variability in disease duration of the fibrosis may affect the
expression of dermatopontin.
To date, regulation of dermatopontin expression by cytokines
has not been studied in detail. Our results clearly indicate that
TGF-β1 stimulates both dermatopontin mRNA and protein levels,
whereas IL-4 reduces dermatopontin expression. TGF-β1 and IL-4
are assumed to be potential candidate molecules in the pathogenesis
of fibrotic skin diseases (Roberts et al, 1986; Salmon et al, 1996).
Therefore, it is likely that these cytokines influence dermatopontin
expression in the development of fibrosis in HS and SSc. SSc skin
fibroblasts express high levels of IL-4 in contrast to normal fibroblasts
(Salmon et al, 1996), suggesting that IL-4 is involved in the
persistent downregulation of dermatopontin expression. Thus, our
results also suggest that reduced expression of dermatopontin in
SSc fibroblasts may be due in part to the effects of IL-4.
In this study we have shown that dermatopontin expression was
clearly reduced on the substrate coated with type I collagen and in
three-dimensional collagen matrices. Collagen matrices alter the
expression of extracellular matrix components and collagenases
(Unemori and Werb, 1986; Eckes et al, 1993; Langholtz et al,
1995). Decorin expression is also reduced in collagen matrices
(Greve et al, 1990). As dermatopontin is tightly bound to decorin
in the extracellular space (Neame et al, 1989; Okamoto et al,
1996), the collagen matrix may decrease the accumulation of
dermatopontin by reduced expression of both dermatopontin
and decorin.
During the initiation and progression of fibrosis various soluble
mediators such as cytokines may induce the unusual accumulation
of collagen, and this marked alteration of collagen composition
may affect dermatopontin expression. TGF-β1 and IL-4 are potent
stimulators of collagen synthesis (Ignotz and Massague, 1986;
Postlethwaite et al, 1992) and therefore may affect dermatopontin
expression in the development of fibrosis in HS and SSc either
directly, or through increasing the collagen matrices around
fibroblasts.
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